



ANALYTICA LTD - ABN 12 006 464 866

## **ASX ANNOUNCEMENT**

## **Expiry of Unlisted Options**

22nd May 2019: Analytica Ltd (ASX: ALT),

The Company advises that the following unlisted options expired on 5pm 22 May 2019:

Number of unlisted options: 6,350,000

Exercise Price: \$0.0733 cents per option

## **Bryan Dulhunty**

Company Secretary.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:









## **About Analytica Limited**

Analytica's lead product is the PeriCoach<sup>®</sup> System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.

